Fusion Antibodies PLC Director changes (9210C)
February 28 2022 - 2:00AM
UK Regulatory
TIDMFAB
RNS Number : 9210C
Fusion Antibodies PLC
28 February 2022
Fusion Antibodies plc
("Fusion" or the "Company")
Director changes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces that Matthew Baker,
PhD, is joining the Board as a Non-Executive Director with effect
from 1 March 2022. Matthew is currently a member of the Company's
Scientific Advisory Panel, details of which were annouced on 14
January 2022 . The Company also announces that Dr Alan Mawson will
be stepping down as a Non-Executive Director of the Company with
effect from 31 March 2022.
Matthew Baker has more than 20 years' experience developing
biologics in biotech and pharma companies and is a research expert
in B and T-cell immunology, including drug immunogenicity. He
co-founded Antitope Ltd, a service based company focused on using
proprietary technologies to humanise antibodies, and was the Chief
Scientific Officer of Abzena plc, an antibody services company,
until 2016. He previously held a Non-Executive Director role at
Oxford Genetics Ltd (trading as Oxgene) and is currently the CEO of
NeoPhore Limited, a private company focused on the discovery and
development of novel small molecule therapies to treat cancer
through stimulation of the immune system. Matthew brings detailed
immunology, antibody and virus-based mammalian display knowledge to
the Board as well as industry and services market insight.
Simon Douglas, Chairman of Fusion, commented: "I am very pleased
to welcome Matthew to the Board of Fusion Antibodies. His extensive
experience of the antibody services business, both from a technical
and commercial perspective, will be a great benefit the Company
going forward. This will be further strengthened by his continuing
role on our Scientific Advisory Panel.
"On behalf of the Board, I would also like to offer our sincere
thanks to Dr Alan Mawson. Alan has contributed greatly to the
Company over many years, both pre and post Fusion's admission to
AIM, and not only as a Director but also as a valuable member of
the Company's committees, most recently the Audit Committee. The
Company has benefited a great deal from his wise advice and
guidance."
AIM Disclosures
Matthew Paul Baker, aged 51, is, or has been during the last
five years, a director or partner of the following companies and
partnerships:
Current: Past:
* Serendipity Endeavours Limited * Oxford Genetics Ltd
* NeoPhore Limited
* 99 Addison Road Management Limited
Matthew Baker does not hold any ordinary shares in the
Company.
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Simon Douglas, Chairman Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke (Sales and Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation
("CRO") company, listed on AIM, providing a range of antibody
engineering services for the development of antibodies for both
therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody
generation, development, characterisation, optimisation, and
small-scale production. These services include antigen expression,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRx(TM) platform and cell line development, producing
antibody generating stable cell lines optimised for use downstream
by the customer to produce material for clinical trials. Since
2012, the Company has successfully sequenced and expressed over 250
antibodies and successfully completed over 200 humanisation
projects for its international customer base, which has included
eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge
science. In this work our world-class humanization and antibody
optimization platforms harness the power of natural somatic
hypermutation (SHM) to ensure the best molecule goes to the clinic.
Fusion Antibodies' growth strategy is based on enabling Pharma and
Biotech companies get to the clinic more effectively, using
molecules with optimized therapeutic profile and enhanced potential
for successful development and approval and, ultimately, on
speeding up the drug discovery and development process. Fusion's
use of SHM to create a fully human antibody library to capture the
human antibody repertoire will address a continuing market need in
antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on
the size and growth rate in the sector, with the market valued at
$135.4 billion in 2018 and forecast to surpass $300 billion by
2025, a CAGR of 14.26%. As of May 2021, there were 100 approved
antibody therapies on the market and more than 570 antibody
therapies in clinical development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASEWFMIEESEDE
(END) Dow Jones Newswires
February 28, 2022 02:00 ET (07:00 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2023 to Apr 2024